A recent report using a goat anti-mouse VEGF polyclonal IgG also showed improved brain microvascular blood flow, reduced capillary stalling by neutrophils, and reduced BBB leakage in the cortex of APP/PS1 mice at 10–14 months of age, suggesting the therapeutic potential of targeting VEGF signaling for AD treatment [11]. This evidence concerns the gene APP and Alzheimer disease.